American Journal of Clinical Medicine Research
ISSN (Print): 2328-4005 ISSN (Online): 2328-403X Website: Editor-in-chief: Dario Galante
Open Access
Journal Browser
American Journal of Clinical Medicine Research. 2019, 7(1), 18-25
DOI: 10.12691/ajcmr-7-1-4
Open AccessArticle

Risk Factor of Human Immunodeficiency virus Encephalopathy in Children

Mia Milanti Dewi1, , Anggraini Alam1 and Nelly Amalia Risan1

1Department of Child Health, Universitas Padjadjaran, Bandung, Indonesia

Pub. Date: February 19, 2019

Cite this paper:
Mia Milanti Dewi, Anggraini Alam and Nelly Amalia Risan. Risk Factor of Human Immunodeficiency virus Encephalopathy in Children. American Journal of Clinical Medicine Research. 2019; 7(1):18-25. doi: 10.12691/ajcmr-7-1-4


HIV-1 viral infections have been found worldwide, including Indonesia. This HIV-1 virus may affect in every group of ages and spread throughout the organs even the central nervous system. The most common complication in central nervous system is HIV encephalopathy (HIVE). HIVE is frequently unrecognized by clinicians. Symptoms of HIVE were included such as growth defect, microcephaly, and symmetrical motoric deficit that occurs for more than 2 months. The aim of this study is to find out the risk factor of HIVE among children in Teratai Clinic, Dr. Hasan Sadikin General Hospital Bandung. This was a cross sectional study conducted in Teratai Clinic, Dr. Hasan Sadikin General Hospital Bandung. All patients fulfilled inclusion criteria underwent anthropometric measurement, anamnesis, and neurologic examination. Analisis data using multivariate logistic regression. Data were processed by SPSS 20. During period of study, 37 (44%) of pediatric patients with HIV were found suffered from HIVE, with mean of age of 71 months (20-153). Most of the patients were delivered spontaneously, breastfed, and living outside Bandung. Significant risk factor of HIVE incidence were age on diagnosis establishment (p= 0,045, 95% CI: 1,02–6,69) and duration of treatment (p=0,006 , 95% CI: 1). Age on diagnosis that established ≤2 years may contribute in HIVE risk factors. Antiretroviral (ARV) treatment > 5 years may reduce risk of HIVE. Duration of treatment was more significant in decreasing risk of HIVE compared with age in diagnosis established. It was concluded that HIV prevalence in this study was 44%. Age ≤ 2 years old when diagnosed as HIV and duration ARV > 5 years are the significant risk factor on HIVE.

encephalopathy microcephaly HIV HIVE Risk Factors

Creative CommonsThis work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit


[1]  Bale JF. Viral infection.of the nervous system. Dalam: Swaiman KF, Ashwal S, Ferriero DM, Schor NF,editor. Pediatric Neurology. Edisi ke 5. China:Elsevier Saunders. 2012.h. 1262-90.
[2]  Yogev R, Chadwick EG.Acquired Immunodeficiency Syndrome (Human Immunodeficiency Virus). Dalam: Kliegman R, Stanton BM, St Geme III JW, Schor NF, Behrman RE, penyunting. Nelson Textbook of Pediatirics, Edisi ke-20. Philadelphia: Elsevier; 2016. hlm. 1645-66.
[3]  World Health Organization. HIV/AIDS. Terdapat pada: [Diunduh tanggal 5 Juli 2016].
[4]  UNAIDS. Global AIDS Up To Date. 2016.
[5]  Kementerian Kesehatan Indonesia. Profil Kesehatan Indonesia 2015. 2016.
[6]  Rahmalia A, Wisaksana R, Meijerink H, Indrati AR, Alisjahbana B, Roeleveld N,dkk. Women with HIV in Indonesia: are they bridging a concentrated epidemic to the wider community? BMC Res Notes. 2015; 8: 1-8.
[7]  Mann TN, Donald KR, Barbara laughton, Lamberts RP, Langerak NG. HIV encephalopathy with bilateral lower limb spasticity: upper limb motor function and level of activity and participation. Dev Med Child Neurol. 2016: 1-5.
[8]  Mann TN, Donald KR, Walker KG, Langerak NG. Resolved lower limb muscle tone abnormalities in children with HIV encephalopathy receiving standard antiretroviral therapy.AIDS Res Ther. 2015; 12: 43: 1-5.
[9]  Donald KA, Walker KG, Kilborn T, Carrara H, Langerak NG, Eley B, dkk. HIV Encephalopathy: Pediatric Case Series Description And Insights From The Clinic Coalface. AIDS Res Ther.2015; 12: 1-10.
[10]  Phanuphak N, Phanuphak P. History of the prevention of mother to child transmission of HIV in Thailand. Journal of virus eradication 2016; 2: 107-9.
[11]  Donald KA, Walker K, Riordan G, Govender R, Wilmshurst J. The neurological complication of HIV/AIDS in childhood. CMEJ. 2012; 30(1): 1-7.
[12]  Miura Y, Koyanagi Y. HIV encephalopathy. JMAJ. 2006; 49: 212-8.
[13]  Cotton MF, Rabie H. Impact of earlier combination antiretroviral therapy on outcomes in children. Wolter Kluwer Health. 2014; 9: 1-6.
[14]  Tardieu M, Chenadec JL, Persoz A, Meyer L, Blanche S, Mayaux MJ. HIV-1 related encephalopathy in infants compared with children and adults. Neurology. 2000; 54: 1089-95.
[15]  Robertson K, Liner J, Meeker RB. Antiretroviral neurotoxicity. J Neurovirol. 2012; 18(5): 388-99.
[16]  Smith L, Adnams C, Eley B. Neurological And Neurocognitive Function Of HIV-Infected Children Commenced On Antiretroviral Therapy. SAJCH. 2008; 2: 108-3.
[17]  Patel K, Ming Xue, Williams PL, Robertson KR, Oleske JM, Seage GR, dkk. Impact Of HAART And CNS-Penetrating Antiretroviral Regimens On HIV Encephalopathy Among Perinatally Infected Children And Adolescents. NIH. 2009; 23: 1893-1901.
[18]  Kundu CK, Samanta M, Bhattacharyya S. HIV encephalopathy masquerading as infantile stroke syndrome:Treatment after antiretroviral did wonders. JPIDS. 2011; 6: 59-62.
[19]  Kurniati N. Pedoman penerapan terapi HIV pada anak. Kementerian Kesehatan Republik Indonesia. 2014.
[20]  Hamid MZA, Aziz NA, Zulfifli ZS, Norlijah O, Azhar RK. Clinical Features And Risk Factors For HIV Encephalopathy in Children. Southesast Asian J Trop Med Pulic Health. 2008; 39(2): 266-72.
[21]  Walker SY, Pierre RB, Christie CD, Chang SM. Neurocognitive function in HIV-positive children in a developing country. Int J Infect Dis. 2013; 17: 862-7.
[22]  Pearson DA, McGrath NM, Nozyce M, Nichols SL, Raskino C, Brouwers P,dkk. Predicting HIV disease progression in children using measures of neuropsychological and neurological functioning. Pediatrics. 2000; 106(6): 1-10.
[23]  Chase C, Ware J, Hittelman J, Blasini I,Smith R, Llorente A, dkk. Early cognitive and motor development among infants born to woman infected with human immunodeficiency virus.women and infatns transmission study group. Pediatrics. 2000; 106(2): E25.
[24]  Sherr L, Croome N, Castaneda K, Bradshaw K, Romero RH. Developmental challenges in HIV infected children-an update systematic review. Children and Youth Services Reviews 2014; 45: 74-89.
[25]  Van Rie A, Harrington PR, Dow A, Robertson K. Neurologic and Neurodevelopmental Manifestations Of Pediatric HIV/AIDS: a global perspective. European Journal of Pediatric Neurologi. 2007; 11: 1-9.
[26]  Le Doare K, Newel M. Neurodevelopment In Children Born To Hiv-Infected Mothers By Infection And Treatment Status. Pediatrics. 2012; 130: e1326-44.
[27]  Muhaimin T. Impact of HIV/AIDS in the family on children’s quality life. Med J Indones. 2010; 19: 280-6.
[28]  Nwaneri DU. HIV/AIDS:Complications and challenges;the Nigerian experience in pediatric practice.Benin Journal of Postgraduate Medicinee. 2007; 9(1): 58-63
[29]  George R, Andronikou S, Plessis Jd, Plessis A-Md, Toorn RV, Maydell A. Central nervous system manifestations of HIV infection in children. Pediatr Radiol. 2009; 39: 575-85.
[30]  Shah SR, Tullu MS, Kamat JR. Clinical Profile of Pediatric HIV Infection from India. Archives of Medical Research. 2004; 36: 24-31.
[31]  Burchett SK, Pizzo PA. HIV Infection in Infants, Children, and Adolescents. Pediatrics in Review. 2003; 6: 186-94.
[32]  Kementerian Kesehatan Republik Indonesia. Dalam: Pedoman Penerapan Terapi HIV Pada Anak. Nia K, editor. 2014.
[33]  Blokhuis C, Kootstra NA, Caan MWA, Pajkrt D. Neurodevelopmental Delay In Pediatric Hiv/Aids:Current Perspectives. Neurobehavioural HIV Medicine. 2016; 7: 1-13.
[34]  Chu C, Selwyn PA. Complication or HIV infection: a systems-based approach. Am Fam Physician. 2011; 83(4): 395-406.
[35]  Calles NR, Evan D, Terlonge D. Pathophysiology of the Human Immunodeficiency Virus. HIV curriculum for the health professional. 2010: 7-14.
[36]  Lowenthal ED, Cruz N,Yin D. Neurologic And Psychiatric Manifestations Of Pediatric Hiv Infection. HIV curriculum for the health professional. 2010: 194-95.
[37]  Elbirt D, Guri KM, Rosenberg SB, Gill H, Attali M, Asher I. HIV-Associated Neurocognitive Disorders (HAND). IMAJ. 2015; 17: 54-9.
[38]  Tahan TT, Bruck I, Burger M, Cruz CR. Neurological profile and neurodevelopment of 88 children infected with HIV and 84 seroconverted children followed from 1995 to 2001. The Brazilian Journal of Infectious Diseases. 2006; 10(5): 322-26.
[39]  Melvin D, Biggs R, Coomer A, Krechevsky D.Monitoring Neurodevelopmental And Neurocognitive Outcomes In The Uk Paediatric Hiv Cohort. CHIVA guidelines. 2012: 1-15.
[40]  Van Ackermann C, Andronikou S, Laughton B, Kidd M, Dobbels E, Innes S, Toorn R, Cotton M. White Matter Signal Abnormalities In Children With Suspected HIV-Related Neurologic Disease On Early Combination Antiretroviral Therapy. Pediatr Infect Dis J. 2014; 33: e207-12.
[41]  Tardie M, Brunelle F, Raybaud C, Ball W, Barret B, Pautard B,dkk. Cerebral MR Imaging in Uninfected Children Born to HIV-Seropositive Mothers and Perinatally Exposed to Zidovudine. AJNR 2005; 26: 695-701.
[42]  Van Arnhem LA, Bunders MJ, Scherpbier HJ, Majoie CB, Reneman L, Frinking O, dkk. Neurologic Abnormalities in HIV-1 Infected Children in the Era of Combination Antiretroviral Therapy. Plos one 2013; 8(5): 1-6.
[43]  Sopiyudin M. Besar Sampel Dalam Penelitian Kedokteran dan Kesehatan. Edisi 4. Epidemiologi Indonesia.2016.